The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.
about
Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT.The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trialPharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients.Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood TransplantationThe effects of topical aqueous sirolimus on tear production in normal dogs and dogs with refractory dry eye.GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT.Thrombotic microangiopathy following haematopoietic stem cell transplant.Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control.
P2860
Q33413498-2BF1C59B-B651-419B-B03A-3AE536253A35Q33424311-7EDC667F-A587-4021-BDF7-0B073C07431BQ34272554-822C6F4F-569A-4FF4-A5D5-86CAE86EC434Q34487408-D457E1EA-0AE5-4C22-B770-12E76740E722Q35231363-B04E76CC-569F-49FB-9A1B-0E5B5A85BCD0Q35231368-84E67F47-EE49-44D3-9267-D2C6E61BCA6DQ36734547-6321AF2B-84D9-4E96-8996-2FEFFC76BAC3Q36777485-349068DF-A525-4DD7-8E9F-13CF384386A6Q38805253-F9F1FAD5-6C90-42D8-A2E7-1FD3D88F6945Q40577820-520CF163-2971-4910-B009-753FD3E9D586Q45069146-9D286F03-0EA6-4417-B68E-F3AC94A36B5DQ48261069-B41872C9-F1C2-4E7E-9265-A338A1573808Q49375853-8FF21599-9132-46E7-9FF5-1D9FE9C6BFC7Q53166890-64976CE5-722E-4A5A-98CE-A909A379EA94
P2860
The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The combination of sirolimus p ...... yclosporine plus mycofenolate.
@en
type
label
The combination of sirolimus p ...... yclosporine plus mycofenolate.
@en
prefLabel
The combination of sirolimus p ...... yclosporine plus mycofenolate.
@en
P2093
P2860
P1433
P1476
The combination of sirolimus p ...... yclosporine plus mycofenolate.
@en
P2093
Carlos Solano
Carmen Martinez
Dolores Caballero
Francisco J Márquez-Malaver
Jordi Sierra
Jose Antonio Perez-Simón
Lourdes Vazquez
Lucía Lopez-Corral
Mónica Cabrero
Rocío Parody
P2860
P304
P356
10.3324/HAEMATOL.2012.065599
P577
2012-10-12T00:00:00Z